Trident Lifeline

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0MKA01014
  • NSEID:
  • BSEID: 543616
INR
300.00
-5 (-1.64%)
BSENSE

Dec 05

BSE+NSE Vol: 6600

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Trident Lifeline
Everest Organics
Gennex Lab.
Haleos Labs Limi
Bafna Pharma.
Lyka Labs
Valiant Laborato
Nectar Lifesci.
Zim Laboratories
Amanta Healthcar
Infinium Pharma
Why is Trident Lifeline Ltd ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.79 times
2
Healthy long term growth as Net Sales has grown by an annual rate of 58.70% and Operating profit at 55.07%
3
With a growth in Net Sales of 45.8%, the company declared Very Positive results in Sep 25
  • NET SALES(Q) At Rs 27.44 cr has Grown at 52.8% (vs previous 4Q average)
  • PBDIT(Q) Highest at Rs 6.38 cr.
  • PBT LESS OI(Q) Highest at Rs 5.37 cr.
4
Increasing Participation by Institutional Investors
  • Institutional investors have increased their stake by 0.52% over the previous quarter and collectively hold 8.12% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Consistent Returns over the last 3 years
  • Along with generating 7.14% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
stock-recommendationReal-Time Research Report
Verdict Report
How much should you buy?
  1. Overall Portfolio exposure to Trident Lifeline should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Trident Lifeline for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Trident Lifeline
7.14%
0.12
60.94%
Sensex
4.83%
0.41
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
58.70%
EBIT Growth (5y)
55.07%
EBIT to Interest (avg)
5.60
Debt to EBITDA (avg)
3.82
Net Debt to Equity (avg)
0.70
Sales to Capital Employed (avg)
0.68
Tax Ratio
18.17%
Dividend Payout Ratio
0
Pledged Shares
3.43%
Institutional Holding
8.12%
ROCE (avg)
7.43%
ROE (avg)
18.70%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
22
Industry P/E
34
Price to Book Value
4.39
EV to EBIT
24.42
EV to EBITDA
18.86
EV to Capital Employed
2.99
EV to Sales
4.85
PEG Ratio
0.27
Dividend Yield
NA
ROCE (Latest)
12.25%
ROE (Latest)
19.78%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Dow Theory
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

21What is working for the Company
NET SALES(Q)

At Rs 27.44 cr has Grown at 52.8% (vs previous 4Q average

PBDIT(Q)

Highest at Rs 6.38 cr.

PBT LESS OI(Q)

Highest at Rs 5.37 cr.

PAT(Q)

At Rs 4.94 cr has Grown at 38.7% (vs previous 4Q average

EPS(Q)

Highest at Rs 4.26

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Trident Lifeline
Net Sales - Quarterly
At Rs 27.44 cr has Grown at 52.8% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 17.96 Cr
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Quarterly
Highest at Rs 27.44 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 6.38 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 5.37 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 5.37 cr has Grown at 35.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 3.98 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 4.94 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 4.94 cr has Grown at 38.7% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 3.56 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 4.26
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)